Early Access Programme

We have completed two clinical studies in a Centre of Excellence hospital in a European capital, and primary care facility serving a Brazilian favela.

 These independently-executed clinically studies showed:

• Comparable results irrespective of use setting – hospitals or primary care

• No environmental aerosol contamination

• No salivary contamination

• Quantification of respiratory pathogen genomes in 100% of symptomatic patients

• Quantification of multiple cytokines

 You can read the study report here or watch a video presentation of these results here.

Both patients and healthcare professionals offered exceptionally positive feedback on the simplicity and reliability of PBM-Hale™.

As we enter scaled manufacturing, PulmoBioMed is developing partnerships with early users seeking to test PBM-Hale™ in areas such as pneumonia, lung cancer, COPD, lung fibrosis, asthma, inflammation, sarcoidosis, etc. 

We appreciate hearing about your needs and views on how best to achieve our vision of leading the field of accurate, secure, non-invasive deep lung sampling.  

If you are interested in early access to PBM-Hale™ please get in touch by using the form below.